

Press Release

NutrigeneAI and CUHK Professor Jack Wong Spotlighted by Major Media for Breakthrough in Vascular Regeneration Therapy

August 28, 2025, Hong Kong –

Professor Jack Wong, Associate Professor at the School of Life Sciences of The Chinese University of Hong Kong (CUHK) and Co-Founder of NutrigeneAI Biotech Limited, has recently been featured in major Hong Kong media, including the Hong Kong Economic Times, Sing Tao Daily, Wen Wei Po, HK01, and the South China Morning Post. These reports highlighted NutrigeneAI's pioneering development of a first-in-class vascular regeneration drug designed to prevent amputations in patients with diabetic foot ulcers and peripheral artery disease (PAD).



According to the Hong Kong Economic Times, the research reflects Hong Kong's growing innovation power, using new imaging and biomedical technologies to target early-stage diseases. Sing Tao Daily reported that the therapy is the world's first drug capable of significantly reducing the risk of tissue necrosis and amputation, offering new hope for diabetic patients.

【創科獻港力】中大血管修復藥下周亮相 天使輪擬募資3000萬

2025-09-08 04:30:38 香港



促血管再生的藥物

Vascular Everything

示意圖

中文大學初創研發

新藥助治療「糖尿腳」

全球首創減組織壞死截肢風險

星島頭條

hket

有公司製新藥促進血管再生 有望治療外周動脈疾病

另外，中大生命科學學院副教授黃永德有份創辦的另一初創公司「NutrigeneAI」，研發「基於I型細胞因子的血管修復生物藥」，透過激活內皮細胞，促進血管再生。團隊以「外周動脈疾病」為首個治療目標，藥物已經取得美國等國際專利，並完成機制性動物實驗。

Hong Kong healthcare and hospitals Hong Kong / Health & Environment

Hong Kong scientists developing new blood flow treatment to aid diabetes patients South China Morning Post

Team of scientists aims to develop an injectable drug and hopes it can also be used to treat peripheral artery disease

Wen Wei Po emphasized that NutrigeneAI plans to raise HK\$30 million in angel funding to accelerate pre-clinical development and clinical translation, signaling strong market interest. Meanwhile, HK01 featured the company at CUHK's Entrepreneurship Day, where NutrigeneAI showcased its innovative achievements in regenerative medicine.

The South China Morning Post noted that Professor Wong's team is developing an injectable drug that could restore blood flow in damaged limbs, potentially offering a non-invasive alternative to stent implantation or bypass surgery. This innovation, according to SCMP, could benefit millions of patients worldwide who currently face high risks of amputation.

Together, these features underscore NutrigeneAI's role as a driving force in biotech innovation, bridging academic research and industrial application in Hong Kong and the Greater Bay Area.



“We are honored to see our work recognized by leading media across Hong Kong,” said Prof. Jack Wong, Founder of NutrigeneAI. “Our goal is to transform scientific breakthroughs into accessible therapies that can reduce suffering and save lives globally.”

With strong recognition from both the media and the scientific community, NutrigeneAI is well positioned to advance its vascular regeneration therapy into clinical development, setting a new benchmark for biomedical innovation in Asia.

---Ends---

Media Contact:

Communications Office
NutrigeneAI Biotech Limited
coby.ke@nutrigeneai.com